Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
- Written by Reporters
- Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.1
- In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001)...
Read more: Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease